首页> 外文期刊>Investigative ophthalmology & visual science >Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits.
【24h】

Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits.

机译:在兔玻璃体内给药后更昔洛韦和膦甲酸的玻璃体内药代动力学和视网膜浓度。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: To perform a detailed pharmacokinetic study and to evaluate the drug levels reached in the retina after the intravitreal administration of ganciclovir and foscarnet to rabbits. METHODS: Retinal and vitreal levels of both drugs were measured by high-performance liquid chromatography at 1, 6, 12, 24, 36, 48, 60, and 72 hours after a single intravitreal injection of 196 microg and 800 microg of ganciclovir and 960 microg of foscarnet to three groups of 24 pigmented rabbits. A noncompartmental pharmacokinetic analysis was used. RESULTS: Both drugs incorporated rapidly into the retina, but no equilibrium was observed between the drug levels in the vitreous humor and retina. Mean ganciclovir levels in vitreous and retina were 179.6 microg/g and 131.3 microg/g (dose of 196 microg), 755.7 microg/g and 381.6 microg/g (dose of 800 microg) at 1 hour after administration, decreasing to 0.1 microg/g, 0.6 microg/g, 0.8 microg/g, and 0.7 microg/g, respectively, by 72 hours. Mean foscarnet levels in vitreous and retina were 944 microg/g and 217.1 microg/g at 1 hour after administration, decreasing to 74 microg/g and 17.1 microg/g, respectively, by 72 hours. Whereas both doses of ganciclovir yielded retinal levels above the mean inhibitory concentration (IC50) of most human cytomegalovirus (CMV) isolates for more than 60 hours, foscarnet retinal levels were lower than the CMV IC50 before 36 hours had elapsed after administration. CONCLUSIONS: The results suggest that the intravitreal administration of ganciclovir has a better pharmacokinetic profile than foscarnet for the treatment of retinitis caused by CMV and other herpes viruses and support the administration of intravitreal ganciclovir twice a week as a treatment for CMV retinitis.
机译:目的:进行玻璃体内更昔洛韦和膦甲酸的玻璃体内给药后,进行详细的药代动力学研究,并评估视网膜中达到的药物水平。方法:分别在玻璃体内注射196克,800毫克更昔洛韦和960克玻璃体内注射后,分别于1、6、12、24、36、48、60和72小时通过高效液相色谱法测定两种药物的视网膜和玻璃体水平微克膦甲酸酯对三组的24只有色兔子。使用非房室药代动力学分析。结果:两种药物均迅速并入视网膜,但在玻璃体液和视网膜中未观察到药物水平的平衡。给药后1小时,玻璃体和视网膜中的更昔洛韦平均水平分别为179.6微克/克和131.3微克/克(剂量为196微克),755.7微克/克和381.6微克/克(剂量为800微克),降至0.1微克/克。到72小时时,分别为g,0.6微克/克,0.8微克/克和0.7微克/克。给药后1小时,玻璃体和视网膜中的平均膦甲酸水平分别为944微克/克和217.1微克/克,到72小时时分别降至74微克/克和17.1微克/克。尽管两种剂量更昔洛韦的视网膜水平都超过了大多数人类巨细胞病毒(CMV)分离株的平均抑制浓度(IC50)超过60小时,但膦甲酸酯视网膜水平低于给药后36小时之前的CMV IC50。结论:结果表明,玻璃体内注射更昔洛韦的药代动力学优于膦甲酸,在由CMV和其他疱疹病毒引起的视网膜炎的治疗中,并支持每周两次玻璃体内注射更昔洛韦作为CMV视网膜炎的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号